Lupin gains on receiving EIR from USFDA for Pithampur Unit-2 Manufacturing Facility
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Lupin is currently trading at Rs. 920.00, up by 7.10 points or 0.78% from its previous closing of Rs. 912.90 on the BSE.
The scrip opened at Rs. 928.00 and has touched a high and low of Rs. 934.90 and Rs. 915.60 respectively. So far 11476 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 934.90 on 12-Jul-2023 and a 52 week low of Rs. 602.80 on 04-Aug-2022.
Last one week high and low of the scrip stood at Rs. 934.90 and Rs. 889.85 respectively. The current market cap of the company is Rs. 41545.73 crore.
The promoters holding in the company stood at 47.08%, while Institutions and Non-Institutions held 42.52% and 10.40% respectively.
Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Pithampur Unit-2 manufacturing facility that manufactures oral solids and ophthalmic dosage forms. The EIR was issued post the last inspection of the facility conducted from March 21 to March 29, 2023. The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
